Overview

Anti-EGFR and Immunotherapy for TN-IBC

Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
To learn if the combination therapy of panitumumab, pembrolizumab, and standard-of-care chemotherapy can help to control inflammatory breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Amgen
Treatments:
Carboplatin
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Paclitaxel
Panitumumab
Pembrolizumab